Italia markets open in 8 hours 13 minutes

China Resources Beer (Holdings) Company Limited (0291.HK)

HKSE - HKSE Prezzo differito. Valuta in HKD.
Aggiungi a portafoglio
65,500+0,750 (+1,16%)
Alla chiusura: 04:08PM HKT
Schermo intero
Chiusura precedente64,750
Aperto65,150
Denaro65,450 x 0
Lettera65,550 x 0
Min-Max giorno64,200 - 66,600
Intervallo di 52 settimane53,350 - 78,600
Volume4.791.735
Media Volume6.998.635
Capitalizzazione212,482B
Beta (5 anni mensile)0,71
Rapporto PE (ttm)146,53
EPS (ttm)0,447
Prossima data utili18 ago 2021
Rendimento e dividendo (forward)0,47 (0,73%)
Data ex dividendo31 ago 2021
Stima target 1A76,15
  • GlobeNewswire

    Zealand Pharma major shareholder announcement: Credit Suisse Group AG, 2021

    Company announcement – No. 71 / 2021 Zealand Pharma major shareholder announcement: Credit Suisse Group AG, 2021 Copenhagen, DK and Boston, MA, November 29, 2021 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholder: Followi

  • GlobeNewswire

    Zealand Pharma announces successful outcome of Phase 1b clinical trial with GLP1-GLP2 dual receptor agonist, dapiglutide

    Company announcement – No. 70 / 2021 Zealand Pharma announces successful outcome of Phase 1b clinical trial with GLP1-GLP2 dual receptor agonist, dapiglutide Dapiglutide was assessed to be safe and well tolerated following 4 weeks of dosing in humansEffects on several biomarkers suggest that clinically relevant exposures of dapiglutide were achieved in the studyZealand will be exploring several potential indications in gastrointestinal and metabolic diseases Copenhagen, November 22, 2021 – Zeala

  • GlobeNewswire

    Total number of shares and voting rights in Zealand Pharma at September 30, 2021

    Company announcement – No. 62 / 2021 Total number of shares and voting rights in Zealand Pharma at September 30, 2021 Copenhagen, DK and Boston, MA, September 30, 2021 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, in accordance with section 32 of the Danish Capital Markets Act, announces the total number of shares and voting rights in the Company at